Advertisement

Search Results

Advertisement



Your search for them matches 6128 pages

Showing 2001 - 2050


breast cancer

High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options

Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...

symptom management
cardio-oncology

Primary Prevention Strategies for Avoiding Cardiotoxicity in Patients With Cancer: A Growing Area of Research

Cancer is not for the faint of heart, and sometimes neither is the treatment, according to information presented during the ASCO20 Virtual Education Program.1 Approximately 30% of patients who receive cancer therapy will have cardiovascular complications.2 What’s more, in anthracycline-treated...

covid-19

Mobilizing to Meet Challenges and Improve Survival for COVID-19–Positive Patients and Health-Care Professionals

Recognizing the COVID-19 crisis “as an opportunity to mobilize the organization to rise in the most difficult challenges” allowed The University of Texas MD Anderson Cancer Center, Houston, to keep mortality rates low for COVID-19–positive patients with cancer and its employees. So said Peter WT...

covid-19

Chasing Cancer: Challenges to Providing Appropriate Care in the Age of COVID-19

The global impact of the novel coronavirus cannot be overstated, but its effects on cancer care delivery in the United States have been particularly far-reaching. The COVID-19 pandemic has resulted in fewer cancer screenings and reduction in the treatment of new cancers. As a result, the National...

NCI, Cancer Research UK Launch Cancer Grand Challenges Partnership

The National Cancer Institute (NCI), part of the National Institutes of Health, will partner with Cancer Research UK to fund Cancer Grand Challenges, an international initiative to address profound and unanswered questions in cancer research. Through Cancer Grand Challenges, the NCI and Cancer...

covid-19

How Delays in Screening and Early Cancer Diagnosis Amid the COVID-19 Pandemic May Result in Increased Cancer Mortality

Earlier this year, as the COVID-19 pandemic was spreading across the United States, federal health officials and cancer societies urged Americans to delay routine cancer screenings and other elective procedures to keep them out of clinics to avoid potential exposure to the coronavirus and to...

American College of Surgeons Launches New Cancer Surgery Standards Program to Improve Quality of Care

The American College of Surgeons Cancer Programs recently launched the Cancer Surgery Standards Program (CSSP), a new initiative that aims to improve the quality of surgical care provided to patients with cancer by implementing standards for cancer surgery and standardizing the way operative data...

lymphoma

Fine-Tuning CAR T-Cell Therapy for Lymphomas

Chimeric antigen receptor (CAR) T-cell therapies are a major advance in the treatment of hematologic malignancies and are making inroads in solid tumors, but there is room for improvement in their design, since not all patients respond, and those who do may relapse. Researchers are studying...

immunotherapy

New Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical Trials

A new study published by Kichenadasse et al in JNCCN—Journal of the National Comprehensive Cancer Network concentrates on how immunotherapy-related adverse events may impact more than one organ in a single patient. This study provides new information on how frequently multiorgan side effects occur...

gynecologic cancers

Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer

Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...

lung cancer
immunotherapy

Is It Time to Add Checkpoint Inhibitors to the Treatment of Locally Advanced Lung Cancer?

After more than 20 years of failed strategies to improve survival rates for locally advanced lung cancers, checkpoint inhibitors have revolutionized therapy, but prognoses still lag behind other tumor types. During the ASCO20 Virtual Education Program, Mark G. Kris, MD, FASCO, a thoracic medical...

cost of care

Web-Based Tool May Help Patients With Cancer Choose the Best Insurance for Their Needs

Given the rising costs of cancer care, many patients with cancer and cancer survivors are challenged by financial toxicity, the burden of care costs. Many struggle to choose a health insurance plan that best meets their needs. Moreover, these challenges are often exacerbated by limited health...

issues in oncology

Developing Policies to Address Patient Racial Bias and Race-Based Provider Requests

Public momentum for efforts to address structural and systemic racism has led many health-care institutions to consider how they can work to bring about positive change. In this column, drawing on important recent work by Kimani Paul-Emile, JD, PhD, Professor of Law at Fordham University School of ...

lung cancer

Two Organizations Collaborate to Evaluate the Utility of Liquid Biopsy in Treating Lung Cancer

The Cancer Research Institute and The Mark Foundation for Cancer Research have launched an innovative clinical trial that aims to demonstrate the utility of liquid biopsy in assessing responses of patients with lung cancer to immunotherapy (ClinicalTrials.gov identifier NCT04093167). If the trial...

Cornelius O. ‘Skip’ Granai, MD, Champion of Cancer Care for Women, Dies at 71

Cornelius O. “Skip” Granai, MD, Founder of the Program in Women’s Oncology at Women & Infants Hospital of Rhode Island, died on June 28, 2020, after a long bout with cancer. Dr. Granai strongly believed that cancer care for women should encompass both breast and gynecologic cancers, according...

Anticipate Difficulties by Patients in Adhering to Tamoxifen Therapy

Patients prescribed tamoxifen may not report when they interrupt or discontinue therapy, according to the results of a study published in the Journal of Clinical Oncology.1 Using blood draws to determine serum levels of tamoxifen among 1,177 premenopausal women with invasive breast cancer, the...

breast cancer

One in Six Premenopausal Women With Invasive Breast Cancer Is Nonadherent to Tamoxifen Therapy

Measuring serum levels of tamoxifen among premenopausal women being treated for invasive breast cancer identified a “worryingly high proportion of patients, one in six, who were nonadherent to therapy at only 1 year after treatment prescription,” researchers reported in the Journal of Clinical...

Dana-Farber Launches New Center for Prevention and Treatment of BRCA-Related Cancers

Of the tens of thousands of genes in cellular DNA, one group of genes is tasked with ensuring that every cell reproduces itself exactly when it divides to make new cells. Perhaps the best known of these genes are the BRCA genes, which if inherited with a significant alteration, confer a markedly...

After Immigrating From India, Neha Vapiwala, MD, FACR, Followed Her Dream of a Career in Medicine

Neha Vapiwala, MD, FACR, Professor and Vice Chair of Education in the Department of Radiation Oncology and newly appointed Dean of Admissions at the Perelman School of Medicine at the University of Pennsylvania (UPenn), Philadelphia, was born in India to parents who aspired to emigrate to the...

David A. Karnofsky’s Early Contributions to Cancer Research Helped Establish Oncology as a Medical Discipline

For nearly 30 years, from the time he was a young resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his death from lung cancer on August 31, 1969, David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the...

multiple myeloma

How to Treat Patients With Multiple Myeloma Cost-Effectively Without Compromising Outcome

The dramatic advances in the diagnosis and treatment of multiple myeloma over the past 20 years have resulted in significant improvements in overall survival, with 5-year relative survival rates now around 50% and more than 60% for patients younger than age 70.1 The proteasome inhibitors...

cost of care

How the First International Summit on Interventional Pharmacoeconomics Is Sparking Discussion on Reducing Cancer Costs

Three years ago, former Chief Executive Officer of ASCO, Allen S. Lichter, MD, Laurence H. Baker, DO, Professor in the Departments of Internal Medicine and Pharmacology at the University of Michigan Medical School in Ann Arbor; Leonard Saltz, MD, a gastrointestinal oncologist at Memorial Sloan...

leukemia
lymphoma

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...

skin cancer
immunotherapy

Researchers Outline Need for Evaluation of Gene-Expression Profiling in Melanoma

A consensus statement published in JAMA Dermatology by an international group of melanoma researchers evaluated the use of prognostic gene-expression profile testing to guide clinical management of melanoma.1 The group cautioned against the routine use of currently available gene-expression...

Heather Brandt, PhD, to Lead Cancer Prevention Community Outreach Projects for St. Jude

St. Jude Children’s Research Hospital has appointed Heather Brandt, PhD, a behavioral scientist with expertise in cancer prevention and control, to lead community outreach and research programs focused on the prevention of human papillomavirus (HPV)-associated cancers through vaccination. In...

covid-19

Repurposing Drugs for the Treatment of COVID-19

A vaccine for COVID-19 is currently the Holy Grail, but even if an effective vaccine were developed on a fast-track timetable, it may be effective in only a percentage of people, judging by existing flu vaccines, which show efficacy rates of approximately 45% and vary year by year. Until we have a...

Pet Therapy: How the Cat I Never Wanted Saved My Life

My husband and I adopted our cat, Franklin, on a cold November day. It was one of the last days Andrew felt well enough to leave the house to go anywhere other than to chemotherapy or a doctor’s appointment. Our news at these appointments had shifted toward the negative, with disease progression...

immunotherapy
lung cancer
cns cancers
leukemia
lymphoma

FDA Pipeline: Priority Reviews for Immunotherapy Dose Regimen, Small Cell Lung Cancer; Fast Track Designations in Brain Cancer and Leukemia

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for a novel dosing regimen for durvalumab as well as for trilaciclib in small cell lung cancer; granted Fast Track designations to treatments for glioblastoma and B-cell acute lymphoblastic leukemia; and issued reports...

covid-19

Updated Registry Data Confirm Higher COVID-19–Related Mortality in Patients With Cancer

“The distressing intersection of COVID-19 and cancer requires the use of large registries to acknowledge diversity,” stated Solange Peters, MD, PhD, President of the European Society for Medical Oncology (ESMO), in her keynote speech at the American Association for Cancer Research (AACR) Virtual...

solid tumors

Tumor Mutational Burden and the Future of Complex Biomarkers

The development of complex biomarkers such as tumor mutational burden (TMB) has enabled clinicians to identify patients more likely to respond to treatment of a variety of cancers, leading to more accurate diagnoses and improved outcomes. Differences in testing assays, however, have produced...

breast cancer
genomics/genetics

Three Novel Genetic Variants Linked to Male Breast Cancer Discovered

Scientists have newly discovered three genetic changes that increase the risk of breast cancer in men. These findings were published by Maguire et al in the Journal of the National Cancer Institute. The researchers identified three common variations in DNA that predispose men to developing breast...

Expert Point of View: Taimur Sher, MBBS, MD

Taimur Sher, MBBS, MD, Associate Professor of Medicine, Hematology and Medical Oncology Consultant, and Director of the Multi-Specialty Amyloidosis Group at the Mayo Clinic in Jacksonville, Florida, told The ASCO Post that shutting down the source of amyloidogenic light-chain production—the...

prostate cancer

In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful

Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...

neuroendocrine tumors

Update on Detecting and Treating Biologically Diverse Neuroendocrine Tumors

Neuroendocrine tumors are rare malignancies that arise in neuroendocrine cells, which can occur throughout the body but are most commonly found in the gastrointestinal tract, lungs, and pancreas. Although most neuroendocrine tumors are indolent and take years to grow, some are aggressive and grow...

ASCO Special Report: Resuming Cancer Care Delivery During the COVID-19 Pandemic

I’m very pleased to be joined by Piyush Srivastava, MD, Past Chair of ASCO’s Clinical Practice Committee. Dr. Srivastava is a practicing gastrointestinal oncologist, Regional Medical Director of the End of Life Options Program, and Director of Outpatient Palliative Care at Kaiser Permanente Walnut...

lung cancer

Having Cancer Has Not Affected Me in Any Negative Way

I have witnessed much sickness and death over my 35-year career as a medical oncologist. During the early years of my career, I had difficulty dealing with the sickness and death I witnessed on a regular basis. As a result, with help from the Hindu scripture of Bhagavad Gita, I have trained my...

issues in oncology

Physicians, New Drugs, and Pharma

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved record numbers of new cancer drugs recently. This is extraordinarily good news for physicians, patients, and drug companies, but it raises important questions as to how effective these drugs are, whether...

cns cancers

A Pioneering Neurosurgeon Shares Hard-Earned Wisdom Gained Along the Road From the Segregated South

For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with noted neurosurgeon Keith L. Black, MD, Chair of Cedars-Sinai Medical Center’s Department of Neurosurgery and Director of the Maxine Dunitz Neurosurgical Institute. During his career, Dr. Black has...

Dr. Jimmie C. Holland’s Research Has Long Underscored the Importance of Caring for the Whole Patient

Jimmie C. Holland, MD, who served as the inaugural Chairman of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center, died on December 24, 2017, at the age of 89. The ASCO Post paid tribute to Dr. Holland in its January 25, 2018, issue. Here, as part of our ...

National Comprehensive Cancer Network Celebrates Its 25th Year

It was February 1996, and the first annual meeting of the National Comprehensive Cancer Network® (NCCN®) was drawing to a close, when Chief Executive Officer (CEO) Bruce R. Ross, MD, invited comments from the floor. An oncologist who had attended at the urging of a friend—somewhat reluctantly—stood ...

Mustafa Raoof, MD, MS, Recognized for Pancreatic Cancer Research

Mustafa Raoof, MD, MS, a surgical oncologist and researcher specializing in gastrointestinal cancers at City of Hope, was recently awarded a Pancreatic Cancer Action Network Career Development Award (PanCAN) and a Young Investigator Award from the National Comprehensive Cancer Network® (NCCN). “I’m ...

gastrointestinal cancer
genomics/genetics

NTRK Fusions in Gastrointestinal Cancers: Rare but Responsive to Treatment

Although NTRK gene fusions occur in less than 5% of gastrointestinal cancers, it looks like they can be targeted successfully with NTRK inhibitors. In a pooled analysis of three clinical trials, 50% of such patients responded to entrectinib, in an updated analysis presented during the 2020 virtual...

Roswell Park Gynecologic Oncologists Awarded Leadership Roles

Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, announced the promotion of three staff members to leadership positions. “The dedication of this trio of physicians to their patients and Roswell Park’s mission is unmatched,” said Dr. Odunsi, who also...

covid-19

Measuring the Impact of the Plunge in Cancer Screenings During the COVID-19 Pandemic

As outbreaks of the COVID-19 pandemic spiked across the country earlier this year, federal health officials and cancer societies advised people to delay seeking routine cancer screenings, including mammograms and colonoscopies, to keep them out of medical centers and away from potential exposure to ...

A First-Generation Daughter of Immigrants, Gita Suneja, MD, Holds Community Service in High Esteem

Radiation oncologist Gita Suneja, MD, was born and reared in St. Louis, the first-generation daughter of two Indian immigrants. “My father came to the United States to pursue a degree in engineering and decided to remain here, feeling it offered greater opportunities for the family,” Dr. Suneja...

issues in oncology

Pediatric Hematologist/Oncologist Yoram Unguru, MD, MS, MA, Explains the Economic Origins of Drug Shortages and Other Ethical Issues

Improvements in protocol-driven clinical trials and supportive care for children and adolescents with cancer have markedly reduced mortality rates over the past 5 decades. Yet, along with clinical advances, oncologists and their young patients with cancer face a host of ethical issues, made more...

supportive care
immunotherapy

ASCO Guideline Supports Continued Use of Dexamethasone for Patients Receiving Checkpoint Inhibitors and Emetogenic Chemotherapy

The ASCO guideline on the use of antiemetics has been updated to include new anticancer agents, antiemetics, and regimens.1 The guideline also addresses a growing concern among some oncologists that corticosteroids and their immunosuppressive abilities could potentially compromise the efficacy of...

supportive care
symptom management

Updated ASCO Guideline Revisits Evidence on Prevention and Treatment of Chemotherapy-Induced Neuropathy

Peripheral neuropathy is one of the most prominent chronic side effects of chemotherapy and can linger for years, causing discomfort as well as impaired functionality and quality of life. Yet oncologists have struggled to identify definitive treatment and prevention strategies. In an effort to help ...

Expert Point of View: Michele Teng, PhD

Study discussant Michele Teng, PhD, of QIMR Berghofer Medical Research Institute, Brisbane, Australia, commented: “Cancer immunotherapy is a new pillar of cancer treatment. The aim is to improve the overall survival of patients with cancer, but there is room for improvement, and various...

issues in oncology

Weathering the Storm: Personal Steps Toward Racial Equity in Oncology

“Of all the forms of inequality, injustice in health is the most shocking and the most inhumane because it often results in physical death. I see no alternative to direct action and creative nonviolence to raise the conscience of the nation.” —Martin Luther King, Jr, speaking before the Medical...

Advertisement

Advertisement




Advertisement